Filing Details
- Accession Number:
- 0001209191-20-038923
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-25 16:33:49
- Reporting Period:
- 2020-06-23
- Accepted Time:
- 2020-06-25 16:33:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1808158 | Repare Therapeutics Inc. | RPTX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1134655 | Ansbert Gadicke | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2020-06-23 | 3,603,161 | $0.00 | 3,603,161 | No | 4 | C | Indirect | See Footnote |
| Common Shares | Acquisiton | 2020-06-23 | 1,288,948 | $0.00 | 4,892,109 | No | 4 | C | Indirect | See Footnote |
| Common Shares | Acquisiton | 2020-06-23 | 500,000 | $20.00 | 5,392,109 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Class A Preferred Shares | Disposition | 2020-06-23 | 3,603,161 | $0.00 | 3,603,161 | $0.00 |
| Common Shares | Class B Preferred Shares | Disposition | 2020-06-23 | 1,288,948 | $0.00 | 1,288,948 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
- The shares are held as follows: 1,636,136 by MPM BioVentures 2014, L.P. ("BV 2014"), 109,128 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 56,317 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,801,580 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Ansbert Gadicke is a managing director of BV LLC and a member of AM BV2014. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC.
- The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares are held as follows: 2,500,885 by BV 2014, 166,805 by BV 2014(B), 86,082 by AM BV2014 and 2,138,337 by UBS Oncology.
- The shares were purchased as follows: 227,042 by BV 2014, 15,143 by BV 2014(B), 7,815 by AM BV2014 and 250,000 by UBS Oncology.
- The shares are held as follows: 2,727,927 by BV 2014, 181,948 by BV 2014(B), 93,897 by AM BV2014 and 2,388,337 by UBS Oncology.
- No securities held by the Reporting Person.
Billionaire Hedge Funds
